Phase III Trial Comparing Doravirine and Dolutegravir-based Treatments for People Living with HIV-1 Who Have Never Received Antiretroviral Therapy
Led by ANRS, Emerging Infectious Diseases · Updated on 2026-07-27
610
Participants Needed
19
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating doravirine as an alternative to dolutegravir in people newly diagnosed with HIV-1 infection who have not yet received treatment. This Phase III, open-label, randomized clinical trial aims to determine if doravirine combined with tenofovir and lamivudine is not less effective than dolutegravir combined with tenofovir and lamivudine or emtricitabine. The study will be conducted across multiple countries including Brazil, Cameroon, Cte dIvoire, France, Mozambique, and Thailand, enrolling 610 participants.
Participants will be randomly assigned to one of two groups one receiving doravirine 100 mg plus tenofovir DF 300 mg and lamivudine 300 mg daily, and the other receiving dolutegravir 50 mg plus tenofovir DF 300 mg and either lamivudine or emtricitabine daily. The treatment period will last for 96 weeks after starting antiretroviral therapy ART, with primary assessment at week 48 to measure viral suppression.
During the study, participants will undergo evaluations to monitor viral load, drug resistance, metabolic health, body weight changes, liver and kidney function, cardiovascular status, and mental health. Adherence to ART will be tracked, and blood samples will be taken to measure drug levels and immune cell counts. The research team will review virological efficacy and safety outcomes at weeks 48 and 96, supporting a comprehensive understanding of the treatments effects over nearly two years of participation.
CONDITIONS
Brief Title
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection
Research Team
B
Boris TCHAKOUNTE YOUNGUI, Dr
O
Olivier MARCY, Dr
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Be at least 18 years old on the day of signing informed consent
Have confirmed HIV-1 infection according to national testing strategies
Have a plasma HIV-1 RNA level of 1,000 copies/mL or higher within 30 days prior to randomization
Have an indication for HIV treatment based on physician assessment and local guidelines
Be treatment-naïve to antiretroviral therapy, including investigational agents
For women or transgender men of childbearing potential: negative pregnancy test and agreement to use contraception
Understand and voluntarily agree to participate by signing informed consent
You will not qualify if you...
Have ongoing pulmonary or extra-pulmonary tuberculosis
Have any condition or circumstance that could interfere with study participation or results
Be infected with HIV-2 or co-infected with HIV-1 and HIV-2
Have received cabotegravir long-acting or dapivirine pre-exposure prophylaxis (PrEP)
Have received oral PrEP or post-exposure prophylaxis (PEP) in the past three months or lack recent negative HIV-1 test
Have documented or suspected resistance to study drugs as defined by resistance screening
Have elevated liver enzymes (AST or ALT >4 times upper limit of normal)
Have impaired kidney function (estimated glomerular filtration rate <60 mL/min/1.73m²)
Have participated in another investigational study within 30 days prior to consent or plan to do so
Have used systemic immunosuppressive therapy or immune modulators within 30 days prior or anticipate needing them
Require prohibited or contraindicated medications per protocol
Have significant hypersensitivity or contraindication to study drugs
Are pregnant, breastfeeding, or planning pregnancy during the study
Have any condition compromising safety or adherence as judged by investigator
Are under guardianship or deprived of freedom by judicial or administrative decision
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 96 weeks
Participants receive daily oral doses of either doravirine plus tenofovir DF and lamivudine, or dolutegravir plus tenofovir DF and either lamivudine or emtricitabine.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase 2 Study Comparing Injectable GS-3242 Plus Lenacapavir Versus Oral Biktarvy in Adults With Suppressed HIV-1
Open-label Study for Continued Access to Gilead HIV Treatments in Children and Adolescents Who Completed Parent Clinical Studies
Evaluating Acceptance and Commitment Therapy Compared to Brief Intervention for Reducing Unhealthy Drinking in Adults with HIV
Overcoming Barriers to Preventing and Treating Cardiometabolic Disorders
in People Living With HIV in the Southeastern United States
Study of Venetoclax to Promote Death of HIV-infected Cells and Reduce HIV Reservoir Size in People Living With HIV on Antiretroviral Therapy
Evaluating Caspofungin Treatment for Pneumocystis Pneumonia in Adults with HIVAIDS
Comparing Caspofungin with Standard TrimethoprimSulfamethoxazole Therapy
Evaluating the Safety and Effectiveness of DolutegravirLamivudine Compared to Other Regimens in Pregnant Women with HIV-1
Phase III Trial Comparing Doravirine and Dolutegravir-based Treatments for People Living with HIV-1 Who Have Never Received Antiretroviral Therapy
Comparing DoravirineLamivudine and DolutegravirLamivudine Dual Therapies to Maintain Viral Control in Adults Living with HIV-1 on Stable Triple Therapy
Evaluating Doravirine Combined Therapy for Rapid Start of HIV-1 Treatment in Adults Without Prior Antiretroviral Use
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Doravirine versus dolutegravir-based regimen in antiretroviral treatment-naive people living with HIV-1 (ANRS0392s ELDORADO): protocol for an international, open-label, randomised, non-inferiority, phase III trial.
Anthony L'hostellier, Charles Kouanfack, Corine Chazallon...